| Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations. | |
| | |
MedLine Citation:
|
PMID: 22291471 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
We have now at our disposal the new rapid-acting insulin analogs, of which insulin lispro was the first to become commercially available. While the differences in pharmacokinetic and pharmacodynamic characteristics are indisputable, the clinical benefits attained by these changes have not been as clear. In the present review, we discuss the structure, pharmacology, and landmark studies related to insulin lispro. The clinical characteristics of insulin lispro are compared with those of insulin regular and other insulin analogs in different clinical situations. Also included are the aspects of quality of life and cost-effectiveness that may modify the modern practitioner's decision to adopt one type of insulin over another. |
| | |
Authors:
|
J Uy; L Fogelfeld; Y Guerra |
Publication Detail:
|
Type: Journal Article Date: 2012-01-10 |
Journal Detail:
|
Title: Diabetes, metabolic syndrome and obesity : targets and therapy Volume: 5 ISSN: 1178-7007 ISO Abbreviation: Diabetes Metab Syndr Obes Publication Date: 2012 |
Date Detail:
|
Created Date: 2012-01-31 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101515585 Medline TA: Diabetes Metab Syndr Obes Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 1-10 Citation Subset: - |
Affiliation:
|
Division of Endocrinology, Diabetes and Metabolism, John H Stroger Jr Hospital of Cook County, Chicago; Department of Endocrinology, Diabetes and Metabolism, Rush University Hospital, Chicago, IL, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-con...
Next Document: Insulin detemir for the treatment of obese patients with type 2 diabetes.